FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213187558> ?p ?o ?g. }

• W4213187558 endingPage "10" @default.
• W4213187558 startingPage "1" @default.
• W4213187558 abstract "In patients with prostate cancer (PC) receiving prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT), higher baseline standardized uptake values (SUVs) are linked to improved outcome. Thus, readers deciding on RLT must have certainty on the repeatability of PSMA uptake metrics. As such, we aimed to evaluate the test-retest repeatability of lesion uptake in a large cohort of patients imaged with 18F-DCFPyL.In this prospective, IRB-approved trial (NCT03793543), 21 patients with history of histologically proven PC underwent two 18F-DCFPyL PET/CTs within 7 days (mean 3.7, range 1 to 7 days). Lesions in the bone, lymph nodes (LN), and other organs were manually segmented on both scans, and uptake parameters were assessed (maximum (SUVmax) and mean (SUVmean) SUVs), PSMA-tumor volume (PSMA-TV), and total lesion PSMA (TL-PSMA, defined as PSMA - TV × SUVmean)). Repeatability was determined using Pearson's correlations, within-subject coefficient of variation (wCOV), and Bland-Altman analysis.In total, 230 pairs of lesions (177 bone, 38 LN, and 15 other) were delineated, demonstrating a wide range of SUVmax (1.5-80.5) and SUVmean (1.4-24.8). Including all sites of suspected disease, SUVs had a strong interscan correlation (R2 ≥ 0.99), with high repeatability for SUVmean and SUVmax (wCOV, 7.3% and 12.1%, respectively). High SUVs showed significantly improved wCOV relative to lower SUVs (P < 0.0001), indicating that high SUVs are more repeatable, relative to the magnitude of the underlying SUV. Repeatability for PSMA-TV and TL-PSMA, however, was low (wCOV ≥ 23.5%). Across all metrics for LN and bone lesions, interscan correlation was again strong (R2 ≥ 0.98). Moreover, LN-based SUVmean also achieved the best wCOV (3.8%), which was significantly reduced when compared to osseous lesions (7.8%, P < 0.0001). This was also noted for SUVmax (wCOV, LN 8.8% vs. bone 12.0%, P < 0.03). On a compartment-based level, wCOVs for volumetric features were ≥22.8%, demonstrating no significant differences between LN and bone lesions (PSMA-TV, P =0.63; TL-PSMA, P =0.9). Findings on an entire tumor burden level were also corroborated in a hottest lesion analysis investigating the SUVmax of the most intense lesion per patient (R2, 0.99; wCOV, 11.2%).In this prospective test-retest setting, SUV parameters demonstrated high repeatability, in particular in LNs, while volumetric parameters demonstrated low repeatability. Further, the large number of lesions and wide distribution of SUVs included in this analysis allowed for the demonstration of a dependence of repeatability on SUV, with higher SUVs having more robust repeatability." @default.
• W4213187558 created "2022-02-24" @default.
• W4213187558 creator A5000331138 @default.
• W4213187558 creator A5000474863 @default.
• W4213187558 creator A5009751893 @default.
• W4213187558 creator A5012074439 @default.
• W4213187558 creator A5016440729 @default.
• W4213187558 creator A5021273661 @default.
• W4213187558 creator A5022354072 @default.
• W4213187558 creator A5024581793 @default.
• W4213187558 creator A5030247543 @default.
• W4213187558 creator A5030727472 @default.
• W4213187558 creator A5031324764 @default.
• W4213187558 creator A5045477158 @default.
• W4213187558 creator A5045592295 @default.
• W4213187558 creator A5049568817 @default.
• W4213187558 creator A5066512949 @default.
• W4213187558 creator A5067187971 @default.
• W4213187558 creator A5071268553 @default.
• W4213187558 creator A5072680474 @default.
• W4213187558 creator A5074150271 @default.
• W4213187558 creator A5078202806 @default.
• W4213187558 creator A5087520734 @default.
• W4213187558 creator A5088874257 @default.
• W4213187558 date "2022-02-23" @default.
• W4213187558 modified "2023-10-18" @default.
• W4213187558 title "High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL" @default.
• W4213187558 cites W1788773500 @default.
• W4213187558 cites W1978508723 @default.
• W4213187558 cites W1994463565 @default.
• W4213187558 cites W1998345392 @default.
• W4213187558 cites W2015795623 @default.
• W4213187558 cites W2021976328 @default.
• W4213187558 cites W2080388929 @default.
• W4213187558 cites W2087824068 @default.
• W4213187558 cites W2127367027 @default.
• W4213187558 cites W2132961058 @default.
• W4213187558 cites W2554535346 @default.
• W4213187558 cites W2590848133 @default.
• W4213187558 cites W2591849683 @default.
• W4213187558 cites W2614800517 @default.
• W4213187558 cites W2799931007 @default.
• W4213187558 cites W2898213320 @default.
• W4213187558 cites W2898441006 @default.
• W4213187558 cites W2924617625 @default.
• W4213187558 cites W2945518652 @default.
• W4213187558 cites W2947342082 @default.
• W4213187558 cites W2947722113 @default.
• W4213187558 cites W2949281899 @default.
• W4213187558 cites W2982404765 @default.
• W4213187558 cites W2991821398 @default.
• W4213187558 cites W2993120116 @default.
• W4213187558 cites W2996012248 @default.
• W4213187558 cites W2999238049 @default.
• W4213187558 cites W3012871658 @default.
• W4213187558 cites W3022545744 @default.
• W4213187558 cites W3040097601 @default.
• W4213187558 cites W3129520566 @default.
• W4213187558 cites W3130934287 @default.
• W4213187558 cites W3131780647 @default.
• W4213187558 cites W3132398728 @default.
• W4213187558 cites W3151521676 @default.
• W4213187558 cites W3170886129 @default.
• W4213187558 doi "https://doi.org/10.1155/2022/7056983" @default.
• W4213187558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35283693" @default.
• W4213187558 hasPublicationYear "2022" @default.
• W4213187558 type Work @default.
• W4213187558 citedByCount "5" @default.
• W4213187558 countsByYear W42131875582022 @default.
• W4213187558 countsByYear W42131875582023 @default.
• W4213187558 crossrefType "journal-article" @default.
• W4213187558 hasAuthorship W4213187558A5000331138 @default.
• W4213187558 hasAuthorship W4213187558A5000474863 @default.
• W4213187558 hasAuthorship W4213187558A5009751893 @default.
• W4213187558 hasAuthorship W4213187558A5012074439 @default.
• W4213187558 hasAuthorship W4213187558A5016440729 @default.
• W4213187558 hasAuthorship W4213187558A5021273661 @default.
• W4213187558 hasAuthorship W4213187558A5022354072 @default.
• W4213187558 hasAuthorship W4213187558A5024581793 @default.
• W4213187558 hasAuthorship W4213187558A5030247543 @default.
• W4213187558 hasAuthorship W4213187558A5030727472 @default.
• W4213187558 hasAuthorship W4213187558A5031324764 @default.
• W4213187558 hasAuthorship W4213187558A5045477158 @default.
• W4213187558 hasAuthorship W4213187558A5045592295 @default.
• W4213187558 hasAuthorship W4213187558A5049568817 @default.
• W4213187558 hasAuthorship W4213187558A5066512949 @default.
• W4213187558 hasAuthorship W4213187558A5067187971 @default.
• W4213187558 hasAuthorship W4213187558A5071268553 @default.
• W4213187558 hasAuthorship W4213187558A5072680474 @default.
• W4213187558 hasAuthorship W4213187558A5074150271 @default.
• W4213187558 hasAuthorship W4213187558A5078202806 @default.
• W4213187558 hasAuthorship W4213187558A5087520734 @default.
• W4213187558 hasAuthorship W4213187558A5088874257 @default.
• W4213187558 hasBestOaLocation W42131875581 @default.
• W4213187558 hasConcept C121608353 @default.
• W4213187558 hasConcept C126322002 @default.
• W4213187558 hasConcept C126838900 @default.
• W4213187558 hasConcept C126894567 @default.

• next